Analysis of the key themes driving M&A activity reveals that precision and personalized medicine accounted for 6 pharmaceutical deals announced in Q2 2023, worth a total value of $220.2m. The $140m acquisition of Aevitas Therapeutics by 4D Molecular Therapeutics was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, precision and personalized medicine-related deal activity decreased by 85% in Q2 2023 compared with the previous quarter’s total of $1.5bn and rose by 145% as compared to Q2 2022. Related deal volume decreased by 14% in Q2 2023 versus the previous quarter and was 200% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Centerview Partners; Ladenburg Thalmann Financial Services; Moelis & Co with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Cooley; Dechert; Dentons Bingham Greenbaum with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2023 – Thematic Intelligence, buy the report here.